Patents Assigned to WAVE LIFE SCIENCES LTD.
  • Patent number: 11407775
    Abstract: The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: August 9, 2022
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Subramanian Marappan, Ik-Hyeon Paik
  • Patent number: 11136346
    Abstract: To provide a chiral reagent or a salt thereof. The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (—NO2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G1 and G2 taken together to form a group of formula (IV).
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: October 5, 2021
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Mamoru Shimizu, Takeshi Wada
  • Publication number: 20210254062
    Abstract: Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use GC thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51 or exon 53, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 19, 2021
    Applicant: WAVE LIFE SCIENCES LTD.
    Inventors: Jason Jingxin Zhang, Chandra Vargeese, Naoki Iwamoto, Chikdu Shakti Shivalila, Nayantara Kothari, Ann Fiegen Durbin, Selvi Ramasamy, Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Subramanian Marappan, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Hailin Yang, Mamoru Shimizu, Prashant Monian
  • Patent number: 11013757
    Abstract: The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 25, 2021
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Jason Jingxin Zhang, Naoki Iwamoto, Christopher J. Francis, Chandra Vargeese, David Charles Donnell Butler, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
  • Patent number: 10815482
    Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 27, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Patent number: 10724035
    Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: July 28, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Meena, Nenad Svrzikapa, Susovan Mohapatra, Christopher J. Francis, Gregory L. Verdine, Anna Sokolovska
  • Patent number: 10696711
    Abstract: To provide a chiral reagent or a salt thereof. The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (—NO2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G1 and G2 taken together to form a group of formula (IV).
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 30, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Mamoru Shimizu, Takeshi Wada
  • Publication number: 20200157545
    Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 21, 2020
    Applicants: WAVE LIFE SCIENCES LTD., WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
  • Patent number: 10590413
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 17, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Patent number: 10479995
    Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 19, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Meena, Nenad Svrzikapa, Susovan Mohapatra, Christopher J. Francis, Gregory L. Verdine, Anna Sokolovska
  • Patent number: 10450568
    Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
    Type: Grant
    Filed: September 23, 2018
    Date of Patent: October 22, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena, Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
  • Patent number: 10428019
    Abstract: The disclosed and claimed compounds are chiral auxiliaries useful for efficiently producing a phosphorus atom-modified nucleic acid derivative with high stereoregularity. The disclosed and claimed compounds include those represented by the following formula (I) or formula (XI) for introducing the chiral auxiliaries.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: October 1, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Takeshi Wada, Mamoru Shimizu
  • Publication number: 20190264267
    Abstract: Among other things, the present disclosure pertains to methods and compositions related to phasing of allelic variants of genetic loci. Phasing of allelic variants of genetic loci on an individual patient's chromosomes is highly valuable for many purposes, including patient stratification for allele-specific therapeutics.
    Type: Application
    Filed: July 24, 2017
    Publication date: August 29, 2019
    Applicant: Wave Life Sciences Ltd.
    Inventors: Hailin YANG, Aaron Jay MORRIS, Vinod VATHIPADIEKAL
  • Publication number: 20190209604
    Abstract: The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 11, 2019
    Applicant: WAVE LIFE SCIENCES LTD.
    Inventors: Jason Jingxin Zhang, Naoki Iwamoto, Christopher J. Francis, Chandra Vargeese, David Charles Donnell Butler, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
  • Patent number: 10329318
    Abstract: Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically stable H-phophonate moiety with a nucleoside/nucleotide.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 25, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Takeshi Wada, Mamoru Shimizu
  • Patent number: 10307434
    Abstract: Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 4, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Gregory L. Verdine, Meena, Naoki Iwamoto
  • Patent number: 10280192
    Abstract: The present application, among other things, provides technologies, e.g., reagents, methods, etc. for preparing oligonucleotides comprising phosphorothiotriesters linkages. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ia or Ib with a silylating reagent to provide a silyloxyphosphonate, and reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa or IIb to provide an oligonucleotide of structure IIIa or IIIb. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ic with a silylating reagent to provide a silyloxyphosphonate, reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc, and then reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide an oligonucleotide of structure IIIc.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: May 7, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Gregory L. Verdine, Meena, Naoki Iwamoto, David Charles Donnell Butler
  • Patent number: 10167309
    Abstract: To provide a chiral reagent or a salt thereof. The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (—NO2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G1 and G2 taken together to form a group of formula (IV).
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: January 1, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Mamoru Shimizu, Takeshi Wada
  • Patent number: 10160969
    Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 25, 2018
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Patent number: 9982257
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: May 29, 2018
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev